Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.40 |
| ▸ | CHUK | O15111 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | FRK | P42685 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4051186 | 0.76 | ADORA2B (0.59) | ADORA2BADORA1ADORA2AMAP4K4ADORA3 | |
| SCHEMBL4048469 | 0.75 | ADORA2A (0.60) | CYP1A2ADORA2BADORA1ADORA2AMAP4K4 | |
| SCHEMBL4050353 | 0.75 | PDE3B (0.44) | GRM5CYP2C19SCN9AKDM4EHPGD | |
| SCHEMBL1445172 | 0.75 | KMO (0.51) | GRM5KDM4EMAP4K4CYP11B2 | |
| SCHEMBL5242020 | 0.73 | ADORA1 (0.49) | CYP1A2ADORA2BADORA1ADORA2AKDM4E | |
| SCHEMBL6765596 | 0.72 | ADORA1 (0.49) | NPSR1CHUKADORA2BADORA1ADORA2A | |
| SCHEMBL2574104 | 0.71 | NPSR1 (0.45) | GRM5NPSR1SCN9AADORA2BADORA1 | |
| SCHEMBL2932218 | 0.71 | CNR1 (0.49) | NPSR1CYP1A2CYP2C9CYP2C19CNR1 | |
| SCHEMBL2932221 | 0.71 | RPS6KA3 (0.40) | NPSR1CYP1A2CYP2C9CYP2C19CNR1 | |
| SCHEMBL4052237 | 0.70 | ADORA2A (0.44) | ADORA2BADORA1ADORA2AKDM4EMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023763-A1 | Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-01-22 | — | — | US | disclosed |
| US-20090023763-A1 | Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-01-22 | — | — | US | disclosed |
| US-20090023763-A1 | Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-01-22 | — | — | US | disclosed |
| EP-1735310-A1 | CONDENSED PYRIDINE DERIVATIVES USEFUL AS A28 ADENOSINE RECEPTOR ANTAGONISTS | Almirall Prodesfarma, S.A. (ES) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005100353-A1 | CONDENSED PYRIDINE DERIVATIVES USEFUL AS A28 ADENOSINE RECEPTOR ANTAGONISTS | ALMIRALL PRODESFARMA, SA (ES) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023763-A1 | Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists | ADORA2B, ADORA2A, ADORA1 | GRM5 942/4885NPSR1 150/4885CYP1A2 659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.